

# CITATION REPORT

List of articles citing

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

DOI: 10.1038/s41423-020-0426-7

Cellular and Molecular Immunology, 2020, 17, 647-649.

**Source:** <https://exaly.com/paper-pdf/77635555/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
304	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. <b>2020</b> , 77, 168-184		6
303	Beyond bulk single-chain sequencing: Getting at the whole receptor. <b>2020</b> , 24, 93-99		6
302	Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment. <b>2020</b> , 11, 570063		8
301	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <b>2020</b> , 33, 108322		35
300	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. <b>2020</b> , 41, 1006-1022		46
299	A systematic review of SARS-CoV-2 vaccine candidates. <b>2020</b> , 5, 237		257
298	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. <b>2020</b> , 8, e00623		7
297	Potential approaches to combat COVID-19: a mini-review. <b>2020</b> , 47, 9939-9949		9
296	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. <b>2020</b> , 18, 3774-3787		11
295	Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. <b>2020</b> , 16, 2913-2920		16
294	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <b>2020</b> , 88, 106885		20
293	Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. <b>2020</b> , 20, 1033-1046		54
292	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. <b>2020</b> , 10, 28243-28266	25	
291	SARS-CoV-2 and cancer: Are they really partners in crime?. <b>2020</b> , 89, 102068		42
290	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. <b>2020</b> , 41, 815-829		66
289	Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. <b>2020</b> , 41, 1141-1149		739
288	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. <b>2020</b> , 27, 950-958		175

287	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019. <b>2020</b> , 222, 1620-1628	35
286	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. <b>2020</b> , 584, 450-456	848
285	Cardiac arrhythmias in patients with COVID-19. <b>2020</b> , 36, 827-836	44
284	Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. <b>2020</b> , 52, 760-763	10
283	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <b>2020</b> , 217,	289
282	Transforming vaccine development. <b>2020</b> , 50, 101413	15
281	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <b>2020</b> , 11, 562264	5
280	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. <b>2020</b> , 5, 180	151
279	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. <b>2020</b> , 5, 212	59
278	Antibody-like proteins that capture and neutralize SARS-CoV-2. <b>2020</b> , 6,	12
277	Antibody response to SARS-Co-V-2, diagnostic and therapeutic implications. <b>2020</b> , 4, 1731	4
276	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. <b>2020</b> , 5,	29
275	The global response to the COVID-19 pandemic: how have immunology societies contributed?. <b>2020</b> , 20, 594-602	10
274	Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. <b>2020</b> , 222, 1965-1973	8
273	In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform. <b>2020</b> , 21, 527	17
272	Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. <b>2020</b> , 12,	5
271	Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. <b>2020</b> , 10, 21447	31
270	Neutralizing monoclonal antibody fails to recognize porcine epidemic diarrhea virus with two regions deleted in spike protein. <b>2020</b> , 251, 108917	0

269	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. <b>2020</b> , 2020, 9465398	18
268	COVID-19 vaccines: Knowing the unknown. <b>2020</b> , 50, 939-943	14
267	COVID-19: Unanswered questions on immune response and pathogenesis. <b>2020</b> , 146, 18-22	65
266	Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. <b>2020</b> , 12,	360
265	Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. <b>2020</b> , 21,	70
264	Cancer and COVID-19: Unmasking their ties. <b>2020</b> , 88, 102041	48
263	Immunology of COVID-19: Current State of the Science. <b>2020</b> , 52, 910-941	962
262	COVID-19: Transmission, prevention, and potential therapeutic opportunities. <b>2020</b> , 508, 254-266	319
261	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. <b>2020</b> , 63, 12256-12274	111
260	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <b>2020</b> , 369, 643-650	724
259	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. <b>2020</b> , 369, 650-655	854
258	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <b>2020</b> , 182, 828-842.e16	485
257	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. <b>2020</b> , 21,	23
256	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. <b>2020</b> , 32, 107918	107
255	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. <b>2020</b> , 1, 100016	79
254	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. <b>2021</b> , 60, 9789-9802	23
253	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. <b>2021</b> , 133, 9873-9886	4
252	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. <b>2021</b> , 538, 192-203	93

251	Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. <b>2021</b> , 31, e2183	19
250	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. <b>2021</b> , 23, 101-110	11
249	Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. <b>2021</b> , 6, 51-58	53
248	Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. <b>2021</b> , 44, 7-17	20
247	Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. <b>2021</b> , 168, 474-485	33
246	Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. <b>2021</b> , 169, 100-117	25
245	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. <b>2021</b> , 26, 311-329	0
244	Neutralizing antibodies targeting SARS-CoV-2 spike protein. <b>2020</b> , 50, 102125	35
243	Optical Biosensors for Virus Detection: Prospects for SARS-CoV-2/COVID-19. <b>2021</b> , 22, 1176-1189	51
242	Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. <b>2021</b> , 58, 32-48	9
241	Integrated photothermal decontamination device for N95 respirators. <b>2021</b> , 11, 1822	5
240	Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. <b>2020</b> , 11, 618685	29
239	Coevolutionary Analysis and Perturbation-Based Network Modeling of the SARS-CoV-2 Spike Protein Complexes with Antibodies: Binding-Induced Control of Dynamics, Allosteric Interactions and Signaling.	
238	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <b>2021</b> , 12, 593223	42
237	The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. <b>2021</b> ,	27
236	Targeting protein-protein interaction interfaces in COVID-19 drug discovery. <b>2021</b> , 19, 2246-2255	8
235	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). <b>2021</b> , 11, 89	15
234	A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics. <b>2021</b> , 166, 697-714	8

233	Highlighting membrane protein structure and function: A celebration of the Protein Data Bank. <b>2021</b> , 296, 100557	14
232	Therapeutic Development in COVID-19. <b>2021</b> , 1318, 435-448	1
231	Exploring COVID-19: Relating the spike protein to infectivity, pathogenicity and Immunogenicity. <b>2021</b> , 5, 001-010	0
230	Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses.	14
229	Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.	2
228	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. <b>2021</b> , 17, e1009352	24
227	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. <b>2021</b> , 17, e1009282	23
226	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <b>2021</b> , 12, 631139	43
225	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <b>2021</b> , 34, 108699	54
224	The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients. <b>2021</b> , 91, 107325	11
223	Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBD) Expressed in. <b>2021</b> , 11,	6
222	Nanotraps for the containment and clearance of SARS-CoV-2.	1
221	Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. <b>2021</b> , 22,	5
220	A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features.	0
219	Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. <b>2021</b> ,	19
218	Modelling the population-level protection conferred by COVID-19 vaccination.	2
217	Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research. <b>2021</b> , 44, 1-6	1
216	Contribution of protein A step towards cost of goods for continuous production of monoclonal antibody therapeutics.	3

215	Nicotinic cholinergic system and COVID-19: In silico identification of interactions between $\alpha$ 7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-CoV and SARS-CoV-2 Spike glycoproteins. <b>2021</b> , 149, 112009	19
214	Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma. <b>2021</b> , 11, 5558	9
213	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. <b>2021</b> , 16, e0248348	41
212	High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics. <b>2021</b> , 3, FDD55	6
211	Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope. <b>2021</b> , 13,	11
210	Repurposing of anticancer phytochemicals for identifying potential fusion inhibitor for SARS-CoV-2 using molecular docking and molecular dynamics (MD) simulations. <b>2021</b> , 1-18	4
209	Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection. <b>2021</b> , 15, 6340-6351	28
208	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. <b>2021</b> ,	24
207	Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2. <b>2021</b> , 6,	5
206	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. <b>2021</b> , 16, 398-411	9
205	3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements.	2
204	Research progress on coronavirus S proteins and their receptors. <b>2021</b> , 166, 1811-1817	2
203	Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. <b>2021</b> , 93, 3211-3218	14
202	Drug discovery and development targeting the life cycle of SARS-CoV-2. <b>2021</b> , 1, 151-165	3
201	The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. <b>2021</b> , 6, 113	15
200	The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants.	
199	Neutralizing monoclonal antibodies for treatment of COVID-19. <b>2021</b> , 21, 382-393	227
198	Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. <b>2021</b> , 136, 111193	14

197	Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors. <b>2021,</b>	1
196	Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. <b>2021, 40, 36-49</b>	4
195	Antibodies and Vaccines Target RBD of SARS-CoV-2. <b>2021, 8, 671633</b>	32
194	Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone. <b>2021, 7, 1545-1554</b>	21
193	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. <b>2021, 12,</b>	24
192	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. <b>2021, 20, 88</b>	12
191	Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants. <b>2021, 290, 114084</b>	1
190	A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model.	3
189	The Mechanisms and Animal Models of SARS-CoV-2 Infection. <b>2021, 9, 578825</b>	13
188	Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. <b>2021, 93, 5260-52768</b>	
187	Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. <b>2021, 8, 670815</b>	5
186	Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. <b>2021, 29, 819-833.e7</b>	215
185	SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies.	2
184	Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. <b>2021, 11,</b>	3
183	Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. <b>2021, 11, 11046</b>	7
182	Micronutrient therapy and effective immune response: a promising approach for management of COVID-19. <b>2021, 49, 1133-1147</b>	1
181	Identification of Cross-Reactive CD8 T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants. <b>2021,</b>	8
180	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <b>2021, 8, e2100985</b>	8



179	Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations. <b>2021</b> , 105, 107874	19
178	Immunological Approaches to the Treatment of New Coronavirus Infection (Review). <b>2021</b> , 13, 81-99	1
177	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <b>2021</b> , 42, 1604061	2
176	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. <b>2021</b> ,	0
175	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. <b>2021</b> , 54, 1290-1303.e7	35
174	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. <b>2021</b> , 54, 1304-1319.e9	41
173	Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera. <b>2021</b> , 13,	7
172	Nanotraps for the containment and clearance of SARS-CoV-2. <b>2021</b> , 4, 2059-2082	14
171	Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine.	2
170	Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. <b>2021</b> , 2, 100329	21
169	Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection.	3
168	Olfactory detection of human odorant signatures in Covid patients by trained dogs.	0
167	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <b>2021</b> , 13,	2
166	The Spike of SARS-CoV-2: Uniqueness and Applications. <b>2021</b> , 12, 663912	2
165	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <b>2021</b> , 4, 1349-1361	0
164	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. <b>2021</b> , 10,	8
163	Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population. <b>2021</b> , 13,	0
162	Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulation. <b>2021</b> , 82, 104503	2

161	Diverse high-affinity DNA aptamers for wild-type and B.1.1.7 SARS-CoV-2 spike proteins from a pre-structured DNA library. <b>2021</b> , 49, 7267-7279	13
160	Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2. <b>2021</b> , 120, 2902-2913	9
159	Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development.	
158	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. <b>2021</b> , 118, 1077-1087	11
157	High-Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wild-Type and B.1.1.7 SARS-CoV-2 in Unprocessed Saliva. <b>2021</b> , 133, 24468	0
156	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <b>2021</b> , 49, 127-138	1
155	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <b>2021</b> , 54, 1853-1868.e7	83
154	High-Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wild-Type and B.1.1.7 SARS-CoV-2 in Unprocessed Saliva. <b>2021</b> , 60, 24266-24274	19
153	Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study. <b>2021</b> , 12, 705441	1
152	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <b>2021</b> , 118, 1077-1087	14
151	Uric acid as a prognostic factor and critical marker of COVID-19. <b>2021</b> , 11, 17791	3
150	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. <b>2021</b> , 133, 25632	0
149	Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening. <b>2021</b> , 1, 1-10	1
148	An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice.	4
147	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. <b>2021</b> , 95, e0143721	5
146	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. <b>2021</b> , 60, 25428-25435	3
145	Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky. <b>2021</b> , 11, 18285	0
144	Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. <b>2021</b> , 148, 1481-1492.e2	7

143	Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. <b>2021</b> , 12, 751584	5
142	The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants. <b>2021</b> , 36, 109679	3
141	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. <b>2021</b> , 297, 101127	2
140	Construction and applications of SARS-CoV-2 pseudoviruses: a mini review. <b>2021</b> , 17, 1574-1580	12
139	Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. <b>2021</b> , 19, 2806-2818	10
138	Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite.	15
137	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <b>2021</b> , 2, 1	6
136	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. <b>2021</b> , 296, 100346	9
135	Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. <b>2020</b> , 1-120	1
134	Coronaviruses pandemics: Can neutralizing antibodies help?. <b>2020</b> , 255, 117836	14
133	Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications. <b>2020</b> , 48, 2851-2863	2
132	Innate immunology in COVID-19-a living review. Part I: viral entry, sensing and evasion. <b>2020</b> , 1, iqaa004	4
131	Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection.	13
130	In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform.	2
129	A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability.	29
128	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.	41
127	CoV-AbDab: the Coronavirus Antibody Database.	10
126	A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding. <b>2020</b> ,	10

125	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. <b>2020,</b>	30
124	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <b>2020</b>	35
123	Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike. <b>2020,</b>	25
122	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <b>2020,</b>	4
121	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <b>2020,</b>	32
120	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.	1
119	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay. <b>2020,</b>	8
118	Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. <b>2020,</b>	6
117	Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection.	1
116	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.	12
115	Rapid Qmix and readQ assay for scalable detection of SARS-CoV-2 antibodies in patient plasma. <b>2020,</b>	3
114	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins.	2
113	The dichotomous and incomplete adaptive immunity in COVID-19.	1
112	Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction.	1
111	Cost-effective serological test to determine exposure to SARS-CoV-2: ELISA based on the receptor-binding domain of the spike protein (Spike-RBDN318-V510) expressed in Escherichia coli.	0
110	SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. <b>2020,</b>	13
109	The quantitative landscape of the neutralizing antibody response to SARS-CoV-2.	2
108	Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2. <b>2020,</b>	4

107	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.	1
106	Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity.	3
105	Cardiac Arrhythmias in Patients with COVID-19: A Systematic review and Meta-analysis.	2
104	Identification of Cross-Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV-2 Immunodominant Epitope and Its Natural Mutant Variants.	3
103	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <b>2021,</b>	3
102	Antibody response patterns in COVID-19 patients with different levels of disease severity—Japan.	1
101	A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2. <b>2020,</b>	8
100	Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Infection as an Innate Antiviral Mechanism.	8
99	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2.	2
98	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. <b>2020, 5,</b>	88
97	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. <b>2020, 5,</b>	40
96	Antibody response to SARS-CoV-2 infection in humans: A systematic review. <b>2020, 15, e0244126</b>	130
95	Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2. <b>2020,</b>	8
94	Perspectives of Immune Therapy in Coronavirus Disease 2019. <b>2020, 35, e176</b>	41
93	Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. <b>2020, 10,</b>	5
92	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <b>2020, 9,</b>	784
91	Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand. <b>2020, 8, e9863</b>	9
90	SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey. <b>2021, 14, 894-947</b>	

89	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. <b>2021</b> , 37, 109928	21
88	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. <b>2021</b> , 33, e2103471	16
87	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <b>2021</b> , 7, 96	5
86	Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection.	2
85	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.	2
84	Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals.	2
83	Plasma from recovered COVID19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay. <b>2020</b> ,	1
82	CORONAVIRUS: Pathology, Immunology and Therapies.. 1-17	
81	Antibody response to SARS-CoV-2 infection in humans: a systematic review.	5
80	An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2.	
79	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <b>2020</b> , 3639618	3
78	A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19. <b>2021</b> , 22,	1
77	Addressing the global surge of COVID-19 cases: Insights from diagnostics, improved treatment strategies, vaccine development and application. <b>2021</b> , 7, 127-139	1
76	Designing a Multi-epitope Peptide Vaccine Against COVID-19 Variants Utilizing In-silico Tools. <b>2021</b> , 15, 592-605	0
75	A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. <b>2021</b> , e2103240	3
74	A human monoclonal antibody potently pan-neutralizes SARS-CoV-2 VOCs by targeting RBD invariant sites.	
73	Overview of Neutralizing Antibodies and Their Potential in COVID-19.. <b>2021</b> , 9,	5
72	Hindrance of the Proteolytic Activity of Neutrophil-Derived Serine Proteases by Serine Protease Inhibitors as a Management of Cardiovascular Diseases and Chronic Inflammation. <b>2021</b> , 9, 784003	3

71	A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features. <b>2021</b> , 3, 290-300	0
70	Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.. <b>2021</b> , 141, 287-296	0
69	Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review.. <b>2022</b> , 640, 114546	2
68	An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives.	0
67	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.. <b>2022</b> , 110368	10
66	RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine.. <b>2022</b> , 22, 87	3
65	Could Lower Testosterone in Older Men Explain Higher COVID-19 Morbidity and Mortalities?. <b>2022</b> , 23,	1
64	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. <b>2022</b> , 13, 462	3
63	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.. <b>2022</b> , 13, 405	13
62	Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.. <b>2022</b> , 14, eabl6141	5
61	Nanodisc-Mediated Conversion of Virustatic Antiviral Antibody to Disrupt Virus Envelope in Infected Cells.. <b>2022</b> , e2101516	0
60	Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics.. <b>2022</b> , 26, 101537	1
59	Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes.. <b>2021</b> , 15, 103631	
58	Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.. <b>2021</b> , 53, 101199	0
57	Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human Immunoglobulin.	
56	Cryo-EM structure of the SARS-CoV-2 Omicron spike.. <b>2022</b> , 110428	12
55	Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2.. <b>2022</b> ,	1
54	Structural basis for antibody resistance to SARS-CoV-2 omicron variant.	3

53	High Affinity Peptides in Processes of IgG Purification, Chromatographic Column Virus Inactivation/Elimination and Titer of Anti-Rubella IgG Enrichment. <b>2022</b> , 3, 044-059	
52	Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. <b>2022</b> , 14, 2031483	2
51	Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response.. <b>2022</b> , 108959	4
50	Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.. <b>2022</b> , e1785	2
49	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns.. <b>2022</b> , 18, e1010340	2
48	Detection, prevention and treatment of COVID-19 and opportunities for nanobiotechnology. 20200181	3
47	Novel photonic methods for diagnosis of SARS-CoV -2 infection.	2
46	Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern.. <b>2022</b> , 5,	0
45	Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.. <b>2022</b> , e0181421	1
44	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.. <b>2022</b> , 7, 114	0
43	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.. <b>2022</b> , e2347	1
42	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.. <b>2022</b> , 200, 105290	1
41	Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives.. <b>2021</b> , 14,	3
40	Earlier Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.. <b>2021</b> , 11, 792202	0
39	Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems.. <b>2022</b> , 14,	0
38	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.. <b>2022</b> , 109, 108786	0
37	Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies.. <b>2022</b> ,	0
36	Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.. <b>2022</b> , 27, 101619	0



35	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.	
34	The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19. <b>2022</b> , 23, 6196	3
33	Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. <b>2022</b> , 23, 6083	2
32	Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin. <b>2022</b> , 108233	0
31	Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern (VOCs): A Small-scale Clinical Trial.	1
30	In Silico Screening of Some Anti-Cancer Drugs Against the Main Protease of COVID-19 Using Molecular Docking. <b>2022</b> , 19,	1
29	Prospects of Biosensors Based on Functionalized and Nanostructured Solitary Materials: Detection of Viral Infections and Other Risks.	1
28	Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2. <b>2022</b> , 49-76	
27	Monoclonal antibodies for diagnostic and therapeutic systems to combat microbial infections. <b>2022</b> , 627-660	
26	The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated vaccine.	2
25	SARS-CoV-2 Epitopes following Infection and Vaccination Overlap Known Neutralizing Antibody Sites. <b>2022</b> , 2022, 1-14	1
24	Discovery of a Phage Peptide Specifically Binding to the SARS-CoV-2 Spike S1 Protein for the Sensitive Phage-Based Enzyme-Linked Chemiluminescence Immunoassay of the SARS-CoV-2 Antigen. <b>2022</b> , 94, 11591-11599	0
23	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <b>2022</b> , 96,	2
22	SARS-CoV -2 spike trimer vaccine expressed in <i>Nicotiana benthamiana</i> adjuvanted with Alum elicits protective immune responses in mice.	0
21	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. <b>2022</b> , 12,	1
20	Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. <b>2022</b> , 23, 10904	0
19	De novo design and Rosetta-based assessment of high-affinity antibody variable regions (Fv) against the SARS-CoV -2 spike receptor binding domain ( RBD ).	0
18	Semantic and population analysis of the genetic targets related to COVID-19 and its association with genes and diseases.	0

- 17 Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment. 13, ○
- 16 Photo-induced force microscopy applied to electronic devices and biosensors. **2022**, ○
- 15 Recent advances of nanotechnology in COVID 19: A critical review and future perspective. **2023**, 9, 100118 ○
- 14 Simultaneous detection of antibody responses to multiple SARS-CoV-2 antigens by a Western blot serological assay. **2022**, 106, 8183-8194 ○
- 13 Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein. **2022**, 12, 1 ○
- 12 Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection. **2022**, 147144 ○
- 11 Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses. 13, ○
- 10 Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2. **2022**, 10, 3274 1
- 9 The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. ○
- 8 Epitope-directed anti-SARS-CoV -2 scFv engineered against the key spike protein region could block membrane fusion. ○
- 7 A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process. **2023**, 205, 106241 ○
- 6 Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RABD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus. **2023**, 9, e15032 ○
- 5 Diagnostic TR-FRET assays for detection of antibodies in patient samples. **2023**, 3, 100421 ○
- 4 Pre-existing immunity to SARS-CoV-2 associates with strong T cell responses induced by inactivated COVID-19 vaccines. **2023**, 95, 1
- 3 An ultrasensitive ELISA to assay femtomolar level SARS-CoV-2 antigen based on specific peptide and tyramine signal amplification. **2023**, 387, 133746 ○
- 2 Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). **2023**, 13, 4471 ○
- 1 Severe COVID-19: Drugs and Clinical Trials. **2023**, 12, 2893 ○